Leo Pharma starts study of eczema tablet for nettle rash

Leo Pharma and JW Therapeutics have started a new clinical trial in Germany, testing a tablet that was originally developed for eczema on nettle rash.

Photo: Leo Pharma / PR

Leo Pharma has started expanding the potential span of the eczema tablet which it bought from Korean firm JW Therapeutics in 2018.

The two parties have therefore launched a trial of the tablet LEO 152020, formerly known as JW1601, as a treatment for cholinergic urticaria, also known as nettle rash.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs